companydata.dkDraupnir Bio ApS: Financial statements 2020
CVR: 38546880
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2020. In 2020, the company reported a net result of DKK -60,620,000 compared with DKK -15,194,060 the year before. Equity amounted to DKK 54,225,000. The solvency ratio was 89.2%.
- Profit/Loss
- -60,620,000 kr.
- Equity
- 54,225,000 kr.
- Total Assets
- 60,790,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | - | -60.6 mio. | 54.2 mio. | - |
| 2019 | - | -15.9 mio. | -15.2 mio. | 52 mio. | 2 |
| 2018 | - | -1.8 mio. | -2.1 mio. | -1.8 mio. | 1 |
How creditworthy is Draupnir Bio ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of September 3, 2020, Robert Andrew Donald Scott has joined the board of directors of Draupnir Bio ApS.
Draupnir Bio ApS has published its annual report for 2019. Gross profit came to DKK -15,909,546, and the net result was DKK -15,194,060.
As of May 25, 2020, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Draupnir Bio ApS.
As of May 25, 2020, A/S PSE 17 NR. 1056 has stepped down as auditor of Draupnir Bio ApS.
As of April 30, 2020, Roel Bulthuis has joined the board of directors of Draupnir Bio ApS.
As of April 30, 2020, Fiona MacLaughlin has left the board of directors of Draupnir Bio ApS.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. Equity amounted to DKK 15,256,000.